RESUMEN
PURPOSE: This phase II trial was designed to evaluate the feasibility, toxicity, response rates, and survival for neoadjuvant chemotherapy and radiotherapy (RT) followed by surgical resection in newly diagnosed patients with surgically staged IIIA non-small-cell lung carcinoma (NSCLC). PATIENTS AND METHODS: Previously untreated patients with NSCLC underwent bronchoscopy, chest and abdominal computed tomography (CT), bone scan, and surgical staging of the mediastinum. Neoadjuvant treatment consisted of concurrent chemotherapy and RT. Patients then underwent surgical resection, which was followed in turn by additional chemotherapy and RT. Chemotherapy included cisplatin 100 mg/m2 on days 1 and 29, vinblastine 3 mg/m2 on days 1 and 3 and 29 and 31, and fluorouracil (5-FU) 30 mg/kg/d by infusion on days 1 to 3 and 29 to 31 (FVP). RT began on day 1 and included 3,000 cGy in 15 fractions. Surgery took place on day 55, and one more cycle of chemotherapy and an additional 3,000 cGy of RT began on day 85. RESULTS: Forty-one eligible patients (median follow-up, 53 months) were studied. N2 disease was present in 80%, whereas 20% had T3N0 or T3N1 lesions. Response to neoadjuvant chemotherapy and RT included no complete responses (CR), 21 (51%) partial responses (PR) or regressions, 19 (46%) stable disease (SD), and one (2%) progressive disease (PD). Thirty-one patients underwent surgery, and 25 were resected. In four of the 25 resection specimens, no viable tumor was present, whereas in three of the six unresectable patients, extensive biopsy results demonstrated only necrotic tumor. The maximum response achieved using all protocol treatment was 27 (66%) CRs, seven (17%) PRs or regression, six (15%) SDs, and one (2%) PD. Toxicity was substantial and primarily hematologic. There were six (15%) treatment-related deaths, which included three perioperative deaths and three chemotherapy-related toxicity deaths. The Kaplan-Meier curve indicated a 1-year survival of 58% and a median survival of 15.5 months. Nine patients (22%) remain disease-free. CONCLUSIONS: There was a reasonably high rate of PR associated with concurrent neoadjuvant chemotherapy and RT, and a high percentage of patients who ultimately were rendered completely disease-free. However, treatment-related morbidity and mortality was common. Median survival seemed to be only modestly improved beyond that achieved with less intensive means of treatment. However, a group has emerged of patients who enjoy prolonged disease-free survival and possible cure.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/terapia , Neoplasias Pulmonares/terapia , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Pulmón de Células no Pequeñas/radioterapia , Carcinoma de Pulmón de Células no Pequeñas/cirugía , Cisplatino/administración & dosificación , Terapia Combinada , Evaluación de Medicamentos , Estudios de Factibilidad , Femenino , Fluorouracilo/administración & dosificación , Humanos , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/radioterapia , Neoplasias Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Análisis de Supervivencia , Resultado del Tratamiento , Vinblastina/administración & dosificaciónRESUMEN
Patients with limited-stage small-cell carcinoma of the lung (SCCL) were randomly assigned to a four-drug chemotherapy program consisting of methotrexate, doxorubicin, cyclophosphamide, and CCNU (MACC) or to a regimen consisting of cyclophosphamide, CCNU, and vincristine alternated with Adriamycin (Adria Laboratories, Columbus, Ohio) and vincristine (CCV/AV). All patients received 4,500 cGy, in a split course, to the primary tumor, mediastinum, and supraclavicular lymph node drainage areas and 3,000 cGy to the whole brain. After four cycles of chemotherapy, patients were randomly assigned to chemotherapy plus methanol extractable residue of BCG (MER-BCG) or no MER-BCG. The complete response frequencies were similar for the two regimens (54% and 48%) as were the median survivals (12.0 and 11.5 months) and the two-year survival rates (15% and 17%). Immunotherapy with MER-BCG did not prolong the time to disease progression or improve survival. Women had a greater chance of achieving a complete remission independent of performance status. There was a complex interaction between sex and the chemotherapy regimens that may have important implications for the design and stratification of future trials in SCCL.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Pequeñas/terapia , Inmunoterapia , Neoplasias Pulmonares/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Vacuna BCG/administración & dosificación , Carcinoma de Células Pequeñas/mortalidad , Terapia Combinada , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Doxorrubicina/administración & dosificación , Doxorrubicina/efectos adversos , Estudios de Evaluación como Asunto , Femenino , Humanos , Lomustina/administración & dosificación , Lomustina/efectos adversos , Neoplasias Pulmonares/mortalidad , Masculino , Metotrexato/administración & dosificación , Metotrexato/efectos adversos , Pronóstico , Dosificación Radioterapéutica , Radioterapia de Alta Energía , Distribución Aleatoria , Factores Sexuales , Factores de Tiempo , Vincristina/administración & dosificación , Vincristina/efectos adversosRESUMEN
This Phase II study was designed to determine the efficacy of two chemotherapy regimens with G-CSF support for patients with advanced non-small cell lung cancer (NSCLC). One-hundred and one patients with Stage IIIB or IV NSCLC and performance status 0-1 were randomized to receive ifosfamide 2.0 g/m2 days 1-3, mesna 400 mg/m2 at 0, 4, 6 h days 1-3, cisplatin 33 mg/m2 days 1-3 or etoposide 200 mg/m2 days 1-3, cisplatin 35 mg/m2 days 1-3. Both groups received G-CSF 5 micrograms/kg SQ day 4 to the post day 11 absolute neutrophil count > 10 000. For the 47 eligible patients receiving ifosfamide/mesna/cisplatin, the response rate was 26% (95% confidence interval: 14-40%) and the median survival 7.5 months (95% confidence interval: 5.8-11.0 months). Grade 3 or worse toxicities were: neutropenia 75%, thrombocytopenia 70%, infection 21%. There were two treatment-related deaths due to infection. For course 1, the median absolute neutrophil count nadir was 1.3, platelet nadir 96 000 and incidence of febrile neutropenia 16%. For the 48 eligible patients receiving etoposide/cisplatin, the response rate was 21% (95% confidence interval: 11-35%) and median survival 5.8 months (95% confidence interval: 4.5-9.7 months). Grade 3 or worse toxicities were: neutropenia 90%, thrombocytopenia 58%, infection 29%. There were three treatment-related deaths due to infection. For course 1, the median absolute neutrophil count was 0.2, platelet nadir 80 000 and incidence of febrile neutropenia 33%. For both ifosfamide/mesna/cisplatin and etoposide/cisplatin, median duration of Grade IV neutropenia was short (< or = 4 days), time to subsequent courses 21 days and dose delivered > 95% of planned dose. Although G-CSF allowed full doses of drugs to be delivered on schedule, both ifosfamide/mesna/cisplatin and etoposide/cisplatin produced response rates and survival similar to other cisplatin-based regimens. In view of the significant cost of G-CSF and no obvious improvement in response rate, survival or toxicity profile, G-CSF cannot be recommended with these chemotherapy regimens for patients with advanced NSCLC.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Cisplatino/administración & dosificación , Esquema de Medicación , Etopósido/administración & dosificación , Femenino , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Humanos , Ifosfamida/administración & dosificación , Masculino , Mesna/administración & dosificación , Persona de Mediana EdadAsunto(s)
Daunorrubicina/uso terapéutico , Leucemia Mieloide/tratamiento farmacológico , Adolescente , Adulto , Factores de Edad , Anciano , Plaquetas , Transfusión Sanguínea , Citarabina/uso terapéutico , Daunorrubicina/administración & dosificación , Daunorrubicina/efectos adversos , Femenino , Humanos , Hidrazinas/uso terapéutico , Hiperplasia/inducido químicamente , Leucemia Mieloide/sangre , Leucemia Mieloide/terapia , Recuento de Leucocitos , Leucopenia/inducido químicamente , Masculino , Mercaptopurina/uso terapéutico , Metotrexato/uso terapéutico , Persona de Mediana Edad , Remisión Espontánea , Trombocitopenia/inducido químicamente , Factores de TiempoAsunto(s)
Encefalopatías , Hemiplejía/etiología , Hepatopatías , Triquinelosis/complicaciones , Adulto , Femenino , HumanosRESUMEN
Forty-eight patients with liver metastases were treated at Rhode ISland Hospital in a nonrandomized sequential manner between January 1972 and June 1977. Eight received 5 FUDR hepatic artery infusion, 14 hepatic irradiation, and 25 were planned for combined intra-arterial chemotherapy plus total hepatic irradiation. Those patients who successfully completed induction treatments had a median survival in the radiation only group of 140 days, in the intra-arterial chemotherapy group 270 days, and in the combined group 376 days. Hepatic radiation when combined with chemotherapy was well tolerated. Primary tumor site, disease duration, and degree of abnormality of liver function had no relationship to the response to treatment. The pretreatment performance level of the patient as determined by the Karnofsky Performance Index gave the best indication for potential response to combined therapy. Based on the results of this treatment and the reports of other series, it appears that the combination of intra-arterial 5 FUDR plus hepatic irradiation may offer prolonged and worthwhile palliation to appropriately chosen patients.
Asunto(s)
Floxuridina/administración & dosificación , Neoplasias Hepáticas/terapia , Médula Ósea/efectos de los fármacos , Femenino , Floxuridina/efectos adversos , Arteria Hepática , Humanos , Infusiones Intraarteriales , Masculino , Metástasis de la Neoplasia/terapia , Radioterapia de Alta Energía , Remisión Espontánea , Factores de Tiempo , Vómitos/inducido químicamenteRESUMEN
Gastrointestinal involvement occurs in a greater proportion of patients with malignant lymphoma of Waldeyer's ring than would be accounted for by change alone. In the absence of direct lymphatic connection between these two sites, the association of these tumors has prompted several hypotheses: that the gastrointestinal lymphoma is a concomitant primary tumor; or that it is related to the swallowing and implantation of tumor cells; or that it represents the homing tendency of the gut-associated lymphoid tissue. Five cases are described in which malignant lymphoma of Waldeyer's ring developed ten months to five and half years after an initial diagnosis of gastrointestinal lymphoma was made. All five patients were female, and the original tumors were of the nodular lymphoma, histiocytic type in 4, and Lennert's lymphoma in 1. The tumors of Waldeyer's ring had similar cytologic features. In 1 patient with small intestinal lymphoma and recurrent tonsillar tumor five and half years later, immunoperoxidase staining of the original and recurrent tumors was positive with anti-IgA and anti-kappa antisera, thus establishing the identity of the two tumors. The reverse pattern of involvement, i.e., Waldeyer's ring tumor following gastrointestinal lymphoma, provides evidence against the concomitant primary or swallowing theories. The homing tendencies of gut-associated lymphoid tissue may offer some explanations for this interesting coincidence.
Asunto(s)
Neoplasias Gastrointestinales/complicaciones , Linfoma/complicaciones , Neoplasias Tonsilares/complicaciones , Adolescente , Adulto , Anciano , Niño , Femenino , Neoplasias Gastrointestinales/inmunología , Neoplasias Gastrointestinales/patología , Humanos , Técnicas para Inmunoenzimas , Inmunoglobulina A/análisis , Cadenas kappa de Inmunoglobulina/análisis , Linfoma/inmunología , Linfoma/patología , Masculino , Persona de Mediana Edad , Neoplasias Tonsilares/inmunología , Neoplasias Tonsilares/patologíaRESUMEN
Thirty-nine patients with clinical Stage I malignant melanoma of the extremities were treated with hyperthermic perfusion chemotherapy using melphalan followed by excision or wide re-excision of the area and regional lymph node dissection. Four patients with positive lymph nodes, on histologic examination, were considered pathologic Stage II. Seventy-two patients with clinical Stage I extremity melanomas, who were treated by conventional surgical methods, served as concurrent controls, and were comparable in the distribution of their various pretreatment characteristics. The actuarial survivals for clinical Stage I perfusion patients calculated by the life-table method at 5, 10, and 15 years were 91%, 86%, and 77%, respectively, and disease-free survivals were 85%, 80%, and 80%, respectively. These figures were significantly better than controls. A Breslow depth of invasion of greater than 1.5 mm showed a significant difference in both clinical and pathologic Stage I disease as compared with the controls. Similarly, perfused patients aged less than or equal to 50 years survived significantly better than controls in both clinical and pathologic Stage I disease. The literature has been reviewed.
Asunto(s)
Quimioterapia del Cáncer por Perfusión Regional , Calor/uso terapéutico , Melanoma/tratamiento farmacológico , Melfalán/uso terapéutico , Terapia Combinada , Extremidades , Femenino , Humanos , Escisión del Ganglio Linfático , Masculino , Melanoma/cirugía , Melfalán/administración & dosificación , Persona de Mediana Edad , Estadificación de Neoplasias , PronósticoRESUMEN
One hundred twenty patients with inoperable metastatic malignant melanoma were randomly allocated to treatment with either a combination of BCNU 150 mg/m2 and vincristine 2 mg/m2 given every 30 days, or one of two regimens of DTIC: 300 mg/m2/day x 6 or 100 mg/m2/8 hours x 18 given every 30 days. Eight of the 51 (16%) patients who were originally treated with the BCNU and vincristine combination had 50% or more objective tumor regression, compared to 6 out of 25 (24%) patients treated with daily injections of DTIC, and 6 out of 21 (29%) patients treated with DTIC injections every 8 hours. The median duration of response to the BCNU and vincristine combination was 60 days, and the median duration of survival from initiation of treatment was 6.5 months in the responders and 3.3 months in the nonresponders. The median duration of response was 90 and 100 days for the daily and 8-hour regimens of DTIC respectively, andthe median duration of survival from commencement of treatment was 8.5 months for the responders and 3.5 months for the nonresponders. None of the 43 patients who failed to respond to the initial treatment program or whose disease progressed after initial improvement responded to the alternate treatment regimen.